Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion

Share this article:
Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion
Low-Risk Bladder Cancer Rarely Progresses to Muscle Invasion

(HealthDay News) -- Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March issue of The Journal of Urology.

Kate D. Linton, of the University of Sheffield in the United Kingdom, and colleagues examined the risk of disease-specific mortality in 699 patients with primary, low-risk, noninvasive (G1pTa) bladder cancer who were followed for a median of 61 months.

During follow-up, the researchers found that 17 patients died of bladder cancer, including 13 of 14 who displayed progression to muscle invasion and four of 19 who exhibited grade progression to high-grade, nonmuscle invasive disease. Tumor weight and low-grade dysplasia in the initial resection specimen were found to be significantly associated with disease-specific mortality. In these patients, the rate of disease-specific mortality was five times higher than in age and gender matched general populations.

"The rate of progression to muscle invasion and disease-specific mortality in patients with low-risk bladder cancer is low but higher than in the general population," the authors write. "Current surveillance regimens failed to detect advancing disease in time to alter its natural history. While a randomized trial is necessary to robustly confirm our findings, these observations question current surveillance regimens."

One author disclosed a financial tie to GlaxoSmithKline; the study was partially supported by a GlaxoSmithKline SK Clinician Scientist fellowship.

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.
close

Next Article in Male Reproductive Cancers

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Male Reproductive Cancers

Tadalafil Doesn't Prevent Post-Radiotherapy ED in Prostate Cancer

Tadalafil Doesn't Prevent Post-Radiotherapy ED in Prostate Cancer

Drug no better than placebo in preventing erectile dysfunction after radiotherapy for prostate cancer

Prostate Cancer Trial Launched for Xofigo

Prostate Cancer Trial Launched for Xofigo

Phase 3 trial launched for Xofigo (radium Ra 223 dichloride; Bayer HealthCare) injection in combination with Zytiga (abiraterone acetate; Janssen) and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic ...

PADT Doesn't Reduce Mortality in Prostate Cancer

PADT Doesn't Reduce Mortality in Prostate Cancer

For localized prostate cancer, primary androgen-deprivation therapy does not prolong survival.